278 research outputs found
Long short‐distance topology modelling of 3D point cloud segmentation with a graph convolution neural network
3D point cloud segmentation is a non-trivial problem due to its irregular, sparse, and unordered data structure. Existing methods only consider structural relationships of a 3D point and its spatial neighbours. However, the inner-point interactions and long-distance context of a 3D point cloud have been less investigated. In this study, we propose an effective plug-and-play module called the Long Short-Distance Topologically Modelled (LSDTM) Graph Convolutional Neural Network (GCNN) to learn the underlying structure of 3D point clouds. Specifically, we introduce the concept of subgraph to model the contextual-point relationships within a short distance. Then the proposed topology can be reconstructed by recursive aggregation of subgraphs, and importantly, to propagate the contextual scope to a long range. The proposed LSDTM can parse the point cloud data with maximisation of preserving the geometric structure and contextual structure, and the topological graph can be trained end-to-end through a seamlessly integrated GCNN. We provide a case study of triple-layer ternary topology and experimental results on ShapeNetPart, Stanford 3D Indoor Semantics and ScanNet datasets, indicating a significant improvement on the task of 3D point cloud segmentation and validating the effectiveness of our research
Split First Dose Administration of Intravenous Daratumumab for the Treatment of Multiple Myeloma (MM) : Clinical and Population Pharmacokinetic Analyses
Introduction: Daratumumab, a human immunoglobulin Gκ monoclonal antibody targeting CD38, is approved as monotherapy and in combination with standard-of-care regimens for multiple myeloma. In clinical studies, the median durations of the first, second, and subsequent intravenous infusions of daratumumab were 7.0, 4.3, and 3.4 h, respectively. Splitting the first intravenous infusion of daratumumab over 2 days is an approved alternative dosing regimen to reduce the duration of the first infusion and provide flexibility for patients and healthcare providers. Methods: The feasibility of splitting the first 16-mg/kg infusion into two separate infusions of 8 mg/kg on Days 1 and 2 of the first treatment cycle was investigated in two cohorts [daratumumab, carfilzomib, and dexamethasone (D-Kd) and daratumumab, carfilzomib, lenalidomide, and dexamethasone (D-KRd)] of the phase 1b MMY1001 study. Additionally, a population pharmacokinetic (PK) analysis and simulations were used to compare the PK profiles of the split first dose regimen with the recommended single first dose regimens of daratumumab in previously approved indications. Results: In MMY1001, following administration of the second half of a split first dose on Cycle 1 Day 2, postinfusion median (range) daratumumab concentrations were similar between split first dose [D-Kd, 254.9 (125.8-435.5) µg/ml; D-KRd, 277.2 (164.0-341.8) µg/ml; combined, 256.8 (125.8-435.5) µg/ml] and single first dose [D-Kd, 319.2 (237.5-394.7) µg/ml]. At the end of weekly dosing, median (range) Cycle 3 Day 1 preinfusion daratumumab concentrations were similar between split first dose [D-Kd, 663.9 (57.7-1110.7) µg/ml; D-KRd, 575.1 (237.9-825.5) µg/ml; combined, 639.2 (57.7-1110.7) µg/ml] and single first dose [D-Kd, 463.2 (355.9-792.9) µg/ml]. The population PK simulations demonstrated virtually identical PK profiles after the first day of treatment for all approved indications and recommended dosing schedules of daratumumab. Conclusion: These data support the use of an alternative split first dose regimen of intravenous daratumumab for the treatment of MM. Trial Registration: ClinicalTrials.gov number, NCT01998971
Split First Dose Administration of Intravenous Daratumumab for the Treatment of Multiple Myeloma (MM) : Clinical and Population Pharmacokinetic Analyses
Introduction: Daratumumab, a human immunoglobulin Gκ monoclonal antibody targeting CD38, is approved as monotherapy and in combination with standard-of-care regimens for multiple myeloma. In clinical studies, the median durations of the first, second, and subsequent intravenous infusions of daratumumab were 7.0, 4.3, and 3.4 h, respectively. Splitting the first intravenous infusion of daratumumab over 2 days is an approved alternative dosing regimen to reduce the duration of the first infusion and provide flexibility for patients and healthcare providers. Methods: The feasibility of splitting the first 16-mg/kg infusion into two separate infusions of 8 mg/kg on Days 1 and 2 of the first treatment cycle was investigated in two cohorts [daratumumab, carfilzomib, and dexamethasone (D-Kd) and daratumumab, carfilzomib, lenalidomide, and dexamethasone (D-KRd)] of the phase 1b MMY1001 study. Additionally, a population pharmacokinetic (PK) analysis and simulations were used to compare the PK profiles of the split first dose regimen with the recommended single first dose regimens of daratumumab in previously approved indications. Results: In MMY1001, following administration of the second half of a split first dose on Cycle 1 Day 2, postinfusion median (range) daratumumab concentrations were similar between split first dose [D-Kd, 254.9 (125.8-435.5) µg/ml; D-KRd, 277.2 (164.0-341.8) µg/ml; combined, 256.8 (125.8-435.5) µg/ml] and single first dose [D-Kd, 319.2 (237.5-394.7) µg/ml]. At the end of weekly dosing, median (range) Cycle 3 Day 1 preinfusion daratumumab concentrations were similar between split first dose [D-Kd, 663.9 (57.7-1110.7) µg/ml; D-KRd, 575.1 (237.9-825.5) µg/ml; combined, 639.2 (57.7-1110.7) µg/ml] and single first dose [D-Kd, 463.2 (355.9-792.9) µg/ml]. The population PK simulations demonstrated virtually identical PK profiles after the first day of treatment for all approved indications and recommended dosing schedules of daratumumab. Conclusion: These data support the use of an alternative split first dose regimen of intravenous daratumumab for the treatment of MM. Trial Registration: ClinicalTrials.gov number, NCT01998971
Measurements of Cabibbo Suppressed Hadronic Decay Fractions of Charmed D0 and D+ Mesons
Using data collected with the BESII detector at storage ring
Beijing Electron Positron Collider, the measurements of relative branching
fractions for seven Cabibbo suppressed hadronic weak decays ,
, and , , and are presented.Comment: 11 pages, 5 figure
Measurements of J/psi Decays into 2(pi+pi-)eta and 3(pi+pi-)eta
Based on a sample of 5.8X 10^7 J/psi events taken with the BESII detector,
the branching fractions of J/psi--> 2(pi+pi-)eta and J/psi-->3(pi+pi-)eta are
measured for the first time to be (2.26+-0.08+-0.27)X10^{-3} and
(7.24+-0.96+-1.11)X10^{-4}, respectively.Comment: 11 pages, 6 figure
BESII Detector Simulation
A Monte Carlo program based on Geant3 has been developed for BESII detector
simulation. The organization of the program is outlined, and the digitization
procedure for simulating the response of various sub-detectors is described.
Comparisons with data show that the performance of the program is generally
satisfactory.Comment: 17 pages, 14 figures, uses elsart.cls, to be submitted to NIM
Measurement of branching fractions for the inclusive Cabibbo-favored ~K*0(892) and Cabibbo-suppressed K*0(892) decays of neutral and charged D mesons
The branching fractions for the inclusive Cabibbo-favored ~K*0 and
Cabibbo-suppressed K*0 decays of D mesons are measured based on a data sample
of 33 pb-1 collected at and around the center-of-mass energy of 3.773 GeV with
the BES-II detector at the BEPC collider. The branching fractions for the
decays D+(0) -> ~K*0(892)X and D0 -> K*0(892)X are determined to be BF(D0 ->
\~K*0X) = (8.7 +/- 4.0 +/- 1.2)%, BF(D+ -> ~K*0X) = (23.2 +/- 4.5 +/- 3.0)% and
BF(D0 -> K*0X) = (2.8 +/- 1.2 +/- 0.4)%. An upper limit on the branching
fraction at 90% C.L. for the decay D+ -> K*0(892)X is set to be BF(D+ -> K*0X)
< 6.6%
Study of
New data are presented on from a sample of 58M
events in the upgraded BES II detector at the BEPC. There is a
conspicuous signal for and a peak at higher mass which
may be fitted with . From a combined analysis with
data, the branching ratio
is at the 95%
confidence level.Comment: 11 pages, 5 figures. Submitted to Phys. Lett.
Direct Measurements of the Branching Fractions for and and Determinations of the Form Factors and
The absolute branching fractions for the decays and
are determined using singly
tagged sample from the data collected around 3.773 GeV with the
BES-II detector at the BEPC. In the system recoiling against the singly tagged
meson, events for and events for decays are observed. Those yield
the absolute branching fractions to be and . The
vector form factors are determined to be
and . The ratio of the two form
factors is measured to be .Comment: 6 pages, 5 figure
Direct Measurement of the Pseudoscalar Decay Constant fD+
The absolute branching fraction of has been directly
measured by an analysis of a data sample of about 33 collected
around GeV with the BES-II at the BEPC. At these energies,
meson is produced in pair as . A total of mesons are reconstructed from this data set. In the
recoil side of the tagged mesons, purely leptonic decay
events of are observed. This yields a branching fraction of
, and a
corresponding pseudoscalar decay constant
MeV.Comment: 7 pages, 8 figures, Submitted to Physics Letters B in October, 200
- …